LivaNova PLC (LIVN) stock plummeted 5.27% in Tuesday's pre-market trading session, underperforming the broader market. The medical technology company reported mixed fourth-quarter results, with earnings beating estimates but revenue missing expectations.
For Q4, LivaNova reported adjusted earnings per share of $0.81, slightly above the consensus estimate of $0.80. However, revenue came in at $321.8 million, missing analysts' expectations of $324.1 million. The company's full-year revenue grew by 3.77% compared to the previous year.
Furthermore, LivaNova's 2025 guidance disappointed investors. The company expects adjusted EPS in the range of $3.65 to $3.75, slightly below the FactSet consensus estimate of $3.66. Revenue growth is projected to be between 5% and 6% on a constant-currency basis and 6% to 7% on an organic basis.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。